Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,973
archived clinical trials in
High Cholesterol

AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
Click here to add this to my saved trials
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
Renstar Medical Research
mi
from
Ocala, FL
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
Renstar Medical Research
mi
from
Ocala, FL
Click here to add this to my saved trials
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
North Georgia Clinical Research
mi
from
Woodstock, GA
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
North Georgia Clinical Research
mi
from
Woodstock, GA
Click here to add this to my saved trials
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
Radiant Research Inc.
mi
from
Chicago, IL
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
Radiant Research Inc.
mi
from
Chicago, IL
Click here to add this to my saved trials
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
Medsphere Medical Research Center
mi
from
Evansville, IN
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
Medsphere Medical Research Center
mi
from
Evansville, IN
Click here to add this to my saved trials
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
Midwest Institute for Clinical Research
mi
from
Indianapolis, IN
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
Midwest Institute for Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
Maine Research Associates
mi
from
Auburn, ME
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
Maine Research Associates
mi
from
Auburn, ME
Click here to add this to my saved trials
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
Health Trends Research
mi
from
Baltimore, MD
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
Health Trends Research
mi
from
Baltimore, MD
Click here to add this to my saved trials
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
Piedmont Medical Research Associates
mi
from
Winston-Salem, NC
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
Piedmont Medical Research Associates
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
Sterling Research Group
mi
from
Cincinnati, OH
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
Sterling Research Group
mi
from
Cincinnati, OH
Click here to add this to my saved trials
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
Coastal Carolina Research Center
mi
from
Goose Creek, SC
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
Coastal Carolina Research Center
mi
from
Goose Creek, SC
Click here to add this to my saved trials
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
Dallas Diabetes and Endocrine Center
mi
from
Dallas, TX
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
Dallas Diabetes and Endocrine Center
mi
from
Dallas, TX
Click here to add this to my saved trials
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
Diabetes and Glandular Disease Research
mi
from
Dallas, TX
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
Diabetes and Glandular Disease Research
mi
from
Dallas, TX
Click here to add this to my saved trials
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
Hampton Roads Center for Clinical Research
mi
from
Norfolk, VA
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
Hampton Roads Center for Clinical Research
mi
from
Norfolk, VA
Click here to add this to my saved trials
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
National Clinical Research, Inc.
mi
from
Richmond, VA
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
National Clinical Research, Inc.
mi
from
Richmond, VA
Click here to add this to my saved trials
A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)
A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy
Status: Enrolling
Updated:  2/21/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)
A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy
Status: Enrolling
Updated: 2/21/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)
A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy
Status: Enrolling
Updated:  2/21/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)
A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy
Status: Enrolling
Updated: 2/21/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)
A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy
Status: Enrolling
Updated:  2/21/2018
Robarts Research Institute
mi
from
London,
A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)
A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy
Status: Enrolling
Updated: 2/21/2018
Robarts Research Institute
mi
from
London,
Click here to add this to my saved trials
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated:  3/6/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated: 3/6/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated:  3/6/2018
Southwestern American Indian Center
mi
from
Phoenix, AZ
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated: 3/6/2018
Southwestern American Indian Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated:  3/6/2018
University of Southern California
mi
from
Los Angeles, CA
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated: 3/6/2018
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated:  3/6/2018
University of Colorado Health Sciences Ctr.
mi
from
Aurora, CO
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated: 3/6/2018
University of Colorado Health Sciences Ctr.
mi
from
Aurora, CO
Click here to add this to my saved trials
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated:  3/6/2018
Louisiana State University
mi
from
Baton Rouge, LA
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated: 3/6/2018
Louisiana State University
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated:  3/6/2018
Johns Hopkins Pro-Health
mi
from
Baltimore, MD
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated: 3/6/2018
Johns Hopkins Pro-Health
mi
from
Baltimore, MD
Click here to add this to my saved trials
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated:  3/6/2018
Diabetes Center
mi
from
Boston, MA
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated: 3/6/2018
Diabetes Center
mi
from
Boston, MA
Click here to add this to my saved trials
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated:  3/6/2018
Joslin Diabetes Center
mi
from
Boston, MA
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated: 3/6/2018
Joslin Diabetes Center
mi
from
Boston, MA
Click here to add this to my saved trials
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated:  3/6/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated: 3/6/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated:  3/6/2018
Northern Navajo Medical Center
mi
from
Shiprock, NM
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated: 3/6/2018
Northern Navajo Medical Center
mi
from
Shiprock, NM
Click here to add this to my saved trials
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated:  3/6/2018
Columbia University
mi
from
New York, NY
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated: 3/6/2018
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated:  3/6/2018
The University of Pennsylvania Medical Center
mi
from
Philadelphia, PA
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated: 3/6/2018
The University of Pennsylvania Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated:  3/6/2018
University of Pittsburgh
mi
from
Pittsburgh, PA
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated: 3/6/2018
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated:  3/6/2018
Miriam Hospital
mi
from
Providence, RI
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated: 3/6/2018
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated:  3/6/2018
University of Tennessee, Memphis
mi
from
Memphis, TN
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated: 3/6/2018
University of Tennessee, Memphis
mi
from
Memphis, TN
Click here to add this to my saved trials
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated:  3/6/2018
Baylor College of Medicine
mi
from
Houston, TX
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated: 3/6/2018
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated:  3/6/2018
University of Texas Health Sciences Center
mi
from
San Antonio, TX
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated: 3/6/2018
University of Texas Health Sciences Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated:  3/6/2018
Univ of Washington
mi
from
Seattle, WA
Look AHEAD: Action for Health in Diabetes
Look AHEAD: Action for Health in Diabetes
Status: Enrolling
Updated: 3/6/2018
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)).
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
Status: Enrolling
Updated:  4/17/2018
Clinical Research Facility
mi
from
Miami, FL
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)).
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
Status: Enrolling
Updated: 4/17/2018
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)).
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
Status: Enrolling
Updated:  4/17/2018
Clinical Research Facility
mi
from
Las Vegas, NV
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)).
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
Status: Enrolling
Updated: 4/17/2018
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)).
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
Status: Enrolling
Updated:  4/17/2018
Clinical Research Facility
mi
from
Mooresville, NC
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)).
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
Status: Enrolling
Updated: 4/17/2018
Clinical Research Facility
mi
from
Mooresville, NC
Click here to add this to my saved trials
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)).
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
Status: Enrolling
Updated:  4/17/2018
Clinical Research Facility
mi
from
Hurst, TX
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)).
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
Status: Enrolling
Updated: 4/17/2018
Clinical Research Facility
mi
from
Hurst, TX
Click here to add this to my saved trials
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)).
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
Status: Enrolling
Updated:  4/17/2018
Research Site
mi
from
Newmarket,
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)).
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
Status: Enrolling
Updated: 4/17/2018
Research Site
mi
from
Newmarket,
Click here to add this to my saved trials
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)).
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
Status: Enrolling
Updated:  4/17/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)).
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
Status: Enrolling
Updated: 4/17/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Children's Hospital Colorado
mi
from
Aurora, CO
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
University of Miami and Jackson Memorial Hospital
mi
from
Miami, FL
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
University of Miami and Jackson Memorial Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Children's Hospital Boston
mi
from
Boston, MA
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Children's Hospital at Montefiore
mi
from
Bronx, NY
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Children's Hospital at Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Children's Hospital of New York, Columbia Presbyterian Medical Center
mi
from
New York, NY
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Children's Hospital of New York, Columbia Presbyterian Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials